AOTMiT: Transparency Council, among others, on drugs for lung cancer and chronic myeloid leukemia

The agenda includes:

Preparation of positions on drug evaluation:

• Lumykras (sotorasibum) under drug program B.6 "Treatment of patients with lung cancer (ICD-10: C34) and pleural mesothelioma (ICD-10: C45)."
• Jakavi (ruxolitinibum) under the drug program "Ruxolitinib treatment of patients with graft-versus-host disease (ICD-10 T86.0)."
• Scemblix (asciminibum) under the drug program "Treatment of patients with chronic myeloid leukemia."

Preparation of an opinion on:

• Continuation of coverage of medicines containing the active substance brentuximabum vedotinum in the indication: differentiation of the dosage description according to the age of patients in the treatment of lymphomas covered by ICD-10 codes C81 and C84.5,
• Continuation of reimbursement coverage of drugs containing the active substance cyproteronum for the indication: F64.0 (according to ICD-10),
• Continuation of coverage of medicines containing the active substance estradiolum for the indication: F64.0 (according to ICD-10).

Source: AOTMiT